Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents-Reference-Cited by-同舟云学术

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents

Published:2019-12-03 Issue:4 Volume:34 Page:1182-1186
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kubasch Anne Sophie,Schulze Freya,Giagounidis Aristoteles,Götze Katharina S.,Krönke Jan^ORCID,Sockel Katja,Middeke Jan Moritz,Chermat Fatiha,Gloaguen Silke,Puttrich Martin,Weigt Carmen,William Doreen,Fenaux Pierre,Schlenk Richard F.,Thiede Christian,Stasik Sebastian,Mies Anna,Adès Lionel,Oelschlägel Uta,Platzbecker Uwe

Funder

Janssen Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-019-0645-z.pdf

Reference16 articles.

1. Nazha A, Sekeres MA. Precision medicine in myelodysplastic syndromes and leukemias: lessons from sequential mutations. Annu Rev Med. 2017;68:127–37.

2. Platzbecker U. Treatment of MDS. Blood 2019;133:1096–107.

3. Komrokji RS. Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents. Clin Lymphoma Myeloma Leuk. 2015;15:S56–9.